Oral KRAS G12D inhibitor GFH375 shows responses in pancreatic cancer
The oral KRAS G12D inhibitor GFH375 produced a confirmed objective response rate of 35.1% in pancreatic ductal adenocarcinoma, according to phase 1 results in Nature Medicine. Median response duration reached 5.6 months. The trial enrolled 74 heavily treated patients with KRAS G12D-mutant advanced solid tumors, including 43 with pancreatic ductal adenocarcinoma. Another 16 participants had non-small cell lung cancer, and 10 had colorectal cancer. Dose-escalation across 22 patients showed no dose-limiting toxicities, establishing a recommended phase 2 dose of 600 mg once daily. One patient died from treatment-related septic shock.
KRAS G12D is the most prevalent RAS mutation in solid tumors and is associated with poor prognosis, occurring mainly in pancreatic ductal adenocarcinoma.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].